<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04934891</url>
  </required_header>
  <id_info>
    <org_study_id>ION547-CS1</org_study_id>
    <nct_id>NCT04934891</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION547</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION547 Administered Subcutaneously to Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of single and multiple&#xD;
      doses of the antisense inhibitor ION547 administered subcutaneously (SC) in healthy&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, double-blind, randomized, placebo-controlled, dose escalation study of&#xD;
      ION547 in up to 76 participants. Participants will be randomized to receive single and&#xD;
      multiple doses of ION547 or placebo SC. The maximum length of participation in the study will&#xD;
      be approximately 34 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE)</measure>
    <time_frame>Up to Day 232</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration of ION547</measure>
    <time_frame>Up to Day 232</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax: Time Taken to Reach Maximal Plasma Concentration of ION547</measure>
    <time_frame>Up to Day 232</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt: Area Under the Plasma Concentration-time Curve From Time Zero to Time t for ION547</measure>
    <time_frame>Up to Day 232</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine 0-24 Hour (hr) Excretion of ION547</measure>
    <time_frame>Up to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in FXII Antigen Levels</measure>
    <time_frame>Up to Day 232</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in FXII Activity Levels</measure>
    <time_frame>Up to Day 232</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ION547</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ascending single multiple doses of ION547 will be administered by SC injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ascending single multiple doses of ION547-matching placebo will be administered by SC injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ION547</intervention_name>
    <description>ION547 will be administered by SC injection.</description>
    <arm_group_label>ION547</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>ION547-matching placebo will be administered by SC injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must have given written informed consent (signed and dated) and any authorizations&#xD;
             required by local law and be able to comply with all study requirements.&#xD;
&#xD;
          2. Healthy males or females 18 to 65, inclusive, at the time of informed consent.&#xD;
&#xD;
          3. Satisfy the following:&#xD;
&#xD;
             a. Females: Women of childbearing potential are not allowed to participate in this&#xD;
             study.&#xD;
&#xD;
          4. b. Males must be abstinent, surgically sterile (vasectomy with negative semen analysis&#xD;
             at Follow-up, or a surgically sterile non-pregnant female partner) or if engaged in&#xD;
             sexual relations with a woman of childbearing potential (WOCBP), participant is&#xD;
             utilizing a highly effective contraceptive method&#xD;
&#xD;
          5. Body mass index (BMI) ≤ 35 kilograms per square meter (kg/m^2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant abnormalities in medical history or physical examination.&#xD;
&#xD;
          2. Screening laboratory results as follows, or any other clinically significant (CS)&#xD;
             abnormalities in screening laboratory values that would render a participant&#xD;
             unsuitable for inclusion:&#xD;
&#xD;
               1. Urine protein/creatinine (P/C) ratio greater than or equal to (≥) 0.2 milligrams&#xD;
                  (mg)/mg.&#xD;
&#xD;
               2. Positive test (including trace) for blood on urinalysis.&#xD;
&#xD;
               3. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin,&#xD;
                  alkaline phosphatase (ALP), serum creatinine, and blood urea nitrogen (BUN) &gt;&#xD;
                  upper limit of normal (ULN).&#xD;
&#xD;
               4. Hemoglobin A1c (HbA1c) &gt; ULN&#xD;
&#xD;
               5. Platelet count &lt; lower limit of normal (LLN)&#xD;
&#xD;
               6. aPTT &gt; ULN&#xD;
&#xD;
               7. INR &gt; 1.4&#xD;
&#xD;
               8. Evidence of uncorrected hypothyroidism or hyperthyroidism based on thyroid&#xD;
                  function results at Screening.&#xD;
&#xD;
          3. Uncontrolled hypertension (blood pressure [BP] &gt; 160/100 millimeters of mercury&#xD;
             [mmHg]).&#xD;
&#xD;
          4. Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or&#xD;
             carcinoma in situ of the cervix that has been successfully treated.&#xD;
&#xD;
          5. Treatment with another investigational drug, biological agent, or device within 1&#xD;
             month of Screening, or 5 half-lives of investigational agent, whichever is longer.&#xD;
&#xD;
          6. Previous treatment with an oligonucleotide (including small interfering ribonucleic&#xD;
             acid [siRNA]) within 4 months of screening if single dose received, or within 12&#xD;
             months of screening if multiple doses received. Exclusion does not apply to Covid-19&#xD;
             messenger ribonucleic acid (mRNA) vaccines.&#xD;
&#xD;
          7. History of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          8. Regular use of alcohol within 6 months prior to screening (&gt; 7 drinks/week for&#xD;
             females, &gt; 14 drinks/week for males [1 drink = 5 ounces (150 mL) of wine or 12 ounces&#xD;
             (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor]), or use of soft drugs (such as&#xD;
             marijuana) within 3 months prior to screening, or hard drugs (such as cocaine and&#xD;
             phencyclidine [PCP]) within 1 year prior to screening, or positive urine drug screen&#xD;
             at Screening.&#xD;
&#xD;
          9. Concomitant medication restrictions: the use of prescription and over-the-counter&#xD;
             medications including nonsteroidal anti-inflammatory drugs (with the exception of&#xD;
             occasional acetaminophen or ibuprofen) and herbal remedies at Screening and throughout&#xD;
             the Study Period.&#xD;
&#xD;
         10. Smoking limitations: more than 10 cigarettes/day at Screening and those with a&#xD;
             significant change in smoking habits within 1 month prior to Screening should be&#xD;
             excluded.&#xD;
&#xD;
         11. Blood donation of 50 to 499 mL within 30 days of Screening or of &gt; 499 mL within 60&#xD;
             days of Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ionis Pharmaceuticals</last_name>
    <phone>(844) 414-1645</phone>
    <email>ionisNCT04934891study@clinicaltrialmedia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>BioPharma Services, Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9L 3A2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>https://www.biopharmaservices.com/volunteers/register/</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Participants</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

